Skip to content
PubMed This is a summary of 13 peer-reviewed journal articles Updated
Pediatric Endocrinology

Long-Term Monitoring and Growing Up with FGD

At a Glance

Children with familial glucocorticoid deficiency need lifelong follow-up to adjust hydrocortisone and monitor growth, learning, puberty, and bone health. Genetic subtype screening and gradual self-management preparation help support a safe, independent adulthood.

Managing Familial Glucocorticoid Deficiency (FGD) is not just about the first year; it is about supporting your child as they grow from an infant into an independent adult. Because FGD is a lifelong condition, the focus shifts over time from stabilization to optimizing growth, development, and quality of life [1][2].

The Routine of Growth

During childhood, you will likely see your pediatric endocrinologist regularly [1]. These visits are more than just check-ups; they are essential for fine-tuning medication.

  • Height and Weight: Your doctor will plot your child’s growth on a curve. If a child grows too slowly, their dose might be too low—or if they grow too quickly or their BMI (Body Mass Index) rises sharply, their dose might be too high [3][4].
  • Bone Age: Occasionally, your doctor may order an X-ray of the hand to check bone age. This helps determine if the hydrocortisone doses are affecting how quickly your child’s skeleton is maturing [3].
  • Blood Pressure: Regular blood pressure checks ensure that the body is handling the medication well and that there are no signs of unexpected salt or fluid imbalances [1].

Neurodevelopment and School Success

For many parents, the biggest concern is how the diagnosis affects the brain. The good news is that with early diagnosis and consistent treatment, many children with FGD have completely normal neurodevelopment [5][6].

However, if your child experienced severe hypoglycemia (low blood sugar) or seizures before they were diagnosed, they may have a higher risk for mild developmental or motor delays [5][7]. It is helpful to:

  • Monitor Milestones: Keep a close eye on early milestones like walking and talking [6].
  • School Support: If you notice struggles with focus, memory, or learning, consider a formal neuropsychological evaluation. This can help you get a 504 Plan or IEP (Individualized Education Program) to ensure they have the support they need in the classroom [7].

Puberty and Beyond the Adrenals

As your child enters their teenage years, new areas of health come into focus.

  • Puberty: In most “classic” FGD cases, puberty happens normally. However, in certain genetic subtypes like NNT, puberty can sometimes be slow or delayed [8][9].
  • Bone Health: Long-term use of excessive hydrocortisone can sometimes lead to lower bone density (osteopenia). Ensuring your child gets enough calcium, Vitamin D, and weight-bearing exercise is important for their future bone strength, and testing may be considered if clinically indicated [8][10].
  • Subtype Screening: If your child has the NNT subtype, your doctor may periodically check their heart (for cardiomyopathy) and thyroid [9]. If they have the SGPL1 subtype, regular urine tests are needed to check for kidney issues (proteinuria) [11][12].

Transitioning to Adulthood

One of the most important goals is the “hand-off” of care. As your child becomes a teenager, they should gradually take the lead based on their readiness:

  1. Self-Dosing: By the early teens or when ready, most children can start setting their own alarms for their daily doses [2].
  2. Emergency Confidence: They should know how to explain their condition to a friend and how to use their own emergency injection kit if they are away from home [2].
  3. Fertility: While fertility is preserved in many cases, some subtypes (like NNT or STAR) may involve reproductive health questions that are best discussed with a specialist in early adulthood [9][13].

Living with FGD requires a partnership between you, your child, and your medical team. With proactive monitoring, the goal is not just to manage a condition, but to ensure your child reaches their full potential [1][2].

Common questions in this guide

How is a child with FGD monitored as they grow?
Children with FGD usually have regular visits with a pediatric endocrinologist. These visits may include height, weight, blood pressure, and sometimes a bone-age X-ray so the team can assess growth and adjust hydrocortisone safely.
Can familial glucocorticoid deficiency affect learning or development?
Many children who are diagnosed early and treated consistently have typical development. Severe low blood sugar or seizures before diagnosis can increase the chance of learning or movement delays, so milestone checks, school feedback, and formal testing may be helpful.
Can FGD affect puberty and bone health?
Puberty is usually normal in classic FGD, but some genetic forms, including NNT-related FGD, can cause slower or delayed puberty. Long-term excessive hydrocortisone can lower bone density, so the care team may discuss calcium, vitamin D, exercise, and testing when needed.
What extra monitoring is needed for NNT or SGPL1-related FGD?
Extra checks depend on the genetic subtype. NNT-related FGD may prompt heart and thyroid monitoring, while SGPL1-related FGD may require urine tests for protein and other signs of kidney problems.
How can a teenager learn to manage FGD independently?
Transition should happen gradually and according to the teenager's readiness. They can practice setting dose reminders, explaining FGD to trusted people, carrying emergency medication, and learning how to use the emergency injection kit before taking more responsibility.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my child's current growth velocity and weight, is their hydrocortisone dose appropriate for their age?
  2. 2.If my child experienced early hypoglycemic seizures, what developmental or educational monitoring should we put in place?
  3. 3.Given our specific genetic subtype (e.g., NNT, SGPL1), what is our individualized screening schedule for other organ systems?
  4. 4.At what age or developmental stage should we evaluate pubertal progression or discuss long-term bone health?
  5. 5.How can we create a readiness-based transition plan to help my child gradually learn to manage their own medication and emergency protocols?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (13)
  1. 1

    Treatment and Follow-up of Non-stress Adrenal Insufficiency

    Buğrul F, Özcan Murat N

    Journal of clinical research in pediatric endocrinology 2025; (17(Suppl 1)):93-101 doi:10.4274/jcrpe.galenos.2024.2024-6-23-S.

    PMID: 39713906
  2. 2

    The management of glucocorticoid deficiency: Current and future perspectives.

    Dineen R, Martin-Grace J, Thompson CJ, Sherlock M

    Clinica chimica acta; international journal of clinical chemistry 2020; (505()):148-159 doi:10.1016/j.cca.2020.03.006.

    PMID: 32145273
  3. 3

    Growth alterations in rare forms of primary adrenal insufficiency: a neglected issue in paediatric endocrinology.

    Ferrigno R, Cioffi D, Pellino V, et al.

    Endocrine 2023; (80(1)):1-9 doi:10.1007/s12020-022-03236-z.

    PMID: 36309634
  4. 4

    Rare Causes of Pediatric Primary Adrenal Insufficiency: An Observational Cohort Study.

    Schermesser-Sicard M, Samara-Boustani D, Roucher-Boulez F, et al.

    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2026; doi:10.1016/j.eprac.2026.05.011.

    PMID: 42142624
  5. 5

    A rare and preventable aetiology of neurodevelopmental delay and epilepsy: familial glucocorticoid deficiency.

    Özbek MN, Demiral M, Unal E, et al.

    Journal of pediatric endocrinology & metabolism : JPEM 2021; (34(11)):1463-1468 doi:10.1515/jpem-2021-0150.

    PMID: 34271604
  6. 6

    Familial glucocorticoid deficiency presenting with hyperpigmentation, gigantism, and motor development delay: a case report.

    Uyangoda K, Kamalanathan P, Mettananda S

    Journal of medical case reports 2019; (13(1)):280 doi:10.1186/s13256-019-2206-5.

    PMID: 31481085
  7. 7

    A Pilot Study Evaluating Therapeutic Response of Different Dosage of Oral Glucocorticoid in Two Children with Familial Glucocorticoid Deficiency Presenting with Diffuse Mucocutaneous Hyperpigmentation.

    Sarkar UK, Sarma N, Debbarma S, et al.

    Indian journal of dermatology 2017; (62(2)):191-194 doi:10.4103/ijd.IJD_716_16.

    PMID: 28400640
  8. 8

    Long-Term Follow-Up of Three Family Members with a Novel NNT Pathogenic Variant Causing Primary Adrenal Insufficiency.

    Krasovec T, Sikonja J, Zerjav Tansek M, et al.

    Genes 2022; (13(5)) doi:10.3390/genes13050717.

    PMID: 35627102
  9. 9

    NNT mutations: a cause of primary adrenal insufficiency, oxidative stress and extra-adrenal defects.

    Roucher-Boulez F, Mallet-Motak D, Samara-Boustani D, et al.

    European journal of endocrinology 2016; (175(1)):73-84 doi:10.1530/EJE-16-0056.

    PMID: 27129361
  10. 10

    Trabecular bone score and sclerostin concentrations in patients with primary adrenal insufficiency.

    Zdrojowy-Wełna A, Halupczok-Żyła J, Słoka N, et al.

    Frontiers in endocrinology 2022; (13()):996157 doi:10.3389/fendo.2022.996157.

    PMID: 36407318
  11. 11

    A retrospective analysis of endocrine disease in sphingosine-1-phosphate lyase insufficiency: case series and literature review.

    Maharaj A, Kwong R, Williams J, et al.

    Endocrine connections 2022; (11(8)).

    PMID: 35904228
  12. 12

    SGPL1 Deficiency: A Rare Cause of Primary Adrenal Insufficiency.

    Settas N, Persky R, Faucz FR, et al.

    The Journal of clinical endocrinology and metabolism 2019; (104(5)):1484-1490 doi:10.1210/jc.2018-02238.

    PMID: 30517686
  13. 13

    A rare cause of primary adrenal insufficiency due to a homozygous Arg188Cys mutation in the STAR gene.

    Burget L, Parera LA, Fernandez-Cancio M, et al.

    Endocrinology, diabetes & metabolism case reports 2018; (2018()) doi:10.1530/EDM-18-0003.

    PMID: 29576868

This page is for informational purposes only and does not constitute medical advice or replace your child's pediatric endocrinology care. Discuss growth, development, medication dosing, genetic-subtype screening, and transition planning with your child's medical team.

Get notified when new evidence is published on Familial glucocorticoid deficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.